Research Collaboration with StateHouse Holdings, Inc. and TUMI Genomics
SpexAI GmbH, TUMI Genomics and StateHouse Holdings, Inc., Announce Research Partnership to Understand the Economic Impact of Hop Latent Viroid on Cannabis Harvests
Impact of HLVd
How does the level of infection impact the final product? This study measures the harvest yield and quality of cannabis plants infected with HLVd.
COLOGNE GERMANY, FORT COLLINS, and SAN DIEGO, August 8th, 2023 - SpexAI GmbH, a game-changing AI-driven imaging company to streamline cannabis cultivation and TUMI Genomics, a leading provider of cannabis diagnostic services and products, announce a collaboration with StateHouse Holdings, Inc., to study the relationship between viroid concentration and subsequent crop yield and quality in hop latent viroid-infected cannabis plants. These collaborative efforts seek to produce a predictive measure for cannabis crop yields based on viroid infection level and frequency.
Hop latent viroid (HLVd, HLV or HpLVd) is a pathogen that threatens cannabis plants, causing significant yield loss and lowering harvest quality. This small, single-stranded RNA molecule can infect the plant without causing obvious symptoms in the vegetative phase, making it difficult to detect and control before it is too late.
Despite the initial identification of HLVd in 2019, very little is known about how this infection impacts yield across various cultivars and how viroid load influences overall loss. This research partnership focuses on understanding the economic impact of harvesting HLVd-infected plants at maturity as well as understanding how the growth stage on initial infection affects yield. This project's data will be used to establish a cost-benefit analysis of cultivating infected plants and help growers understand how the level and stage of infection impact this ratio.
Tassa Saldi, Ph.D., Co-Founder and CSO at TUMI Genomics
Since its initial detection, HLVd testing, prevention, and treatment have been at the forefront of research studies in the cannabis industry. However, this particular research partnership focuses on understanding the economic impact of harvesting HLVd-infected plants at maturity. This project's data will be used to establish a cost-benefit analysis of cultivating an infected plant.
“While HLVd causes major economic losses in the cannabis industry, we don’t really have a complete understanding of how much is lost to this viroid and how viroid load impacts outcome,” said Dr. Tassa Saldi, Chief Science Officer. “This research collaboration is really exciting because we will be able to use the results to shape guidelines and predictions for cultivators dealing with HLVd-infected plants. Knowing how the growth stage of infection impacts yield will allow us to fine-tune phytosanitary recommendations depending on predicted threats during clone, veg, and flower stages. The data produced will allow us to help growers develop the most efficient, cost-effective pathogen mitigation programs possible.“
Travis Higginbotham, VP of Cultivation at StateHouse Holdings, Inc.
Under this collaboration, StateHouse cultivators will work with TUMI Genomics to conduct research on HLVd, including selecting strains with stronger HLVd resistance and analyzing how viroid concentration impacts crop yield and quality. In this experiment, multiple cannabis strains will be tested for viroid levels from mother to clone and onto vegetative and flowering stages and compared against non-infected controls TUMI Genomics will provide testing throughout the experiment using its validated pathogen tests and the TUMIGlow™testing platform.
"Understanding and mitigating the devastating effects of Hop Latent Viroid on Cannabis production is not just critical, its imperative to the future of this burgeoning industry. Statehouse's partnership with leaders in plant pathology and smart farming technology signifies a significant step forward in ensuring sustainable cannabis cultivation,” said Travis Higginbotham, VP of Cultivation at StateHouse Holdings, Inc. “We firmly believe that harnessing the collective technical expertise of this consortium is not merely an option, but a singular pathway to a resilient, productive, and thriving cannabis industry."
Ben Niehaus, Co-Founder and Chief Technology Officer
Uniquely positioned, SpexAI will leverage its pioneering multispectral imaging device Hugin and advanced deep neural networks Odin, conducting daily scans on all plants and strains. The ultimate objective is gathering data and revolutionizing early HLVd detection to preempt potential outbreaks. This proactive approach from SpexAI ensures that early signs of infection are identified, enhancing overall plant health and productivity.
"HLVd stealthily compromises cannabis cultivation. Our exploratory research at SpexAI, leveraging Hugin and Odin, aims to shed light on this hidden adversary, opening new possibilities in early viroid detection. It's not just about solving a problem - it's about pioneering a new path in the industry," said Ben Niehaus, Co-Founder and Chief Technology Officer.
The results of this collaboration are expected to have far-reaching consequences for the cannabis industry. This research will further understanding of HLVd biology, develop data-driven recommendations that will help cultivators assess crop ROI, and provide initial insights on the viroid resistance of various strains.
Furthermore, the integration of advanced technology will showcase a new standard in production methodologies, leading to more precise and efficient strategies for maintaining crop health and maximizing productivity.
About SpexAI
SpexAI is integrating advanced technology with nature to revolutionize plant production, focusing on simplifying cultivation processes for a sustainable future. By making actionable the invisible facets of plant growth, they provide data-driven insights into variables that directly affect crop quality, yield, and profitability. A key offering of SpexAI is its chemical imaging capability, allowing them to generate a unique spectral fingerprint for every plant. This feature supports real-time, non-destructive analysis of THC and CBD levels and early detection of diseases and pests, fundamentally transforming standards within the cannabis industry. Guided by a team with an extensive background and entrepreneurial acumen, SpexAI's operations are spearheaded by Ben Niehaus. His expertise in digital phenotyping, honed through projects with Bayer, BASF, and Syngenta, and his contribution to the creation of the world's largest agricultural robot, funded by The Bill and Melinda Gates Foundation, ensures SpexAI is at the forefront of technological innovation in plant production.
Contact: Nadine Walther, Co-Founder and CEO: nadine@spexai.com
Research Inquiries: Ben Niehaus, Co-Founder and CTO: ben@spexai.com
About StateHouse Holdings, Inc.
StateHouse Holdings, Inc. is a leading California cannabis company. With its superior cultivation, processing, manufacturing, distribution and retail operations, StateHouse is a vertically integrated, tier-one company that maximizes returns at every stage of the cannabis value chain.
Media Contact: Angela Pih, Head of Marketing: angela.pih@statehouse.co
Research Inquiries: Rachel Edwards, Manager of R&D: rachel.edwards@statehouse.co
About TUMI Genomics
TUMI Genomics is advancing cannabis cultivation by bringing biological insights to help commercial growers thrive. Through comprehensive preventative solutions, superior pathogen diagnostics, and AI-driven insights, TUMI Genomics is helping cultivators start clean and stay clean. The unrivaled diagnostics, transparent validation and industry-leading pathogen detection innovations provided by TUMI Genomics are raising the standards of commercial cannabis cultivation. The team at TUMI Genomics is composed of deeply experienced Ph.D. molecular biologists, bioinformaticians, business strategists, and accomplished serial entrepreneurs.
Media Contact: Hailey Spencer, Marketing Director: hailey@tumigenomics.com
Research Inquiries: Tassa Saldi, Ph.D., Co-Founder and CSO: tassa@tumigenomics.com